ASH News Daily - Monday, December 12, 2011 - (Page A-15)
Monday, December 12, 2011
LYMPHOMA
QUALITY
Spotlight on Lymphoma: The Latest on Biology
And Biologic Treatments
The Importance of Quality Indicators —
By aManda Brandow, do, MS
By BarBara pro, Md
I
treatment of lymphoma. In Room
5AB, San Diego Convention Center,
from 7:30 to 9:00 a.m., there will be
an oral session (abstracts 949-954)
which will focus on how biologic
determinants affect the outcome of
diffuse large B-cell lymphoma (DL-
A
What You Need to Know Now
Center. In particular, presenters
will discuss how quality indicator
measures are derived, how they can
be measured, the potential consequences
of failure to adhere to these
indicators, and the challenges that
quality indicators pose to particular
hematologic populations.
Dr. Richard Lottenberg, Univer-
This afternoon, attendees will have
the opportunity to learn about the
importance of quality indicators at
the ASH special symposium, “Quality
Indicators: Examples of Relevance
to Hematology” that will be
held from 2:00 to 3:30 p.m. in Room
30 of the San Diego Convention
f you are a lymphomaniac, be early
and bright tomorrow morning
to learn the latest on biology and
re established quality indicators
of sufficient quality
for individual populations?
BCL). Highlights will include the
emerging role of t(14;18) as negative
prognostic indicator in patients with
DLBCL and germinal center B-cell
subtype, the impact of the immune
microenvironment on the outcome
of patients of DLBCL, and the revisited
role of our cheap but loyal friend
immunohistochemistry. Information
obtained from these studies will
hopefully enable us to stratify patients
for more specific therapies.
sity of Florida, Gainesville, will discuss
the challenges in defining the
quality of health care for patients
with sickle cell disease (SCD). Spe-
session will be held in Room 6B,
San Diego Convention Center, from
7:30 to 9:00 a.m., and will focus on
new emerging therapies for nonHodgkin
and Hodgkin lymphomas
(abstracts 955-960). Dr. James Rubenstein
will present the latest on
safety and efficacy of intraventricular
rituximab for patients with recurrent
CNS lymphoma when used in
two different doses and in combi-
cifically, Dr. Lottenberg will discuss
how the small number of randomized,
controlled trials in SCD poses
challenges for the development of
quality indicators. In addition, he
will present recent developments
relevant to the establishment of quality
indicators in SCD and the benefits
of having well-defined quality
indicators in SCD. Dr. Lottenberg
will highlight how operationalizing
quality indicators in SCD is a work
in progress, since there are real chal-
The second Simultaneous Oral
An innovative approach to improving outcomes in patients with cancer
This could allow potent
Antibody-drug conjugates (ADCs) use a conditionally stable linker to combine the targeting specificity of
monoclonal antibodies with the tumor-killing power of potent cytotoxic agents.1,2
drugs to be delivered directly to tumor cells with minimal systemic toxicity.
Optimizing the parameters for clinical success
Scientists at Seattle Genetics are focused on parameters critical to the effective performance of ADCs,
including target antigen selection,3,4 linker stability5-7 and potent cytotoxic agents.4,7,8
and potent cytotoxic agents.4,7,8
Elements of an antibody-drug conjugate
Linker
Antibody
specific for a tumor-associated
antigen that has restricted
expression on normal cells4,8
Antibody
specific for a tumor-associated
antigen that has restricted
expression on normal cells4,8
Cytotoxic agent
kills target cells when
internalized and released4,8
Cytotoxic agent
kills target cells when
internalized and released4,8
attaches the cytotoxic agent to
the antibody. Newer linker
systems are designed to be
systemically stable and release
the cytotoxic agent in
targeted cancer cells4,8,9
attaches the cytotoxic agent to
the antibody. Newer linker
systems are designed to be
systemically stable and release
the cytotoxic agent in
targeted cancer cells4,8,9
Linker ADCs link precision and
potency for greater activity
A preclinical (in vivo) study demonstrated
that the ADC is more active than the
antibody alone (mAb) or the admixture
(mAb + cytotoxic agent unlinked)10
A preclinical (in vivo) study demonstrated
that the ADC is more active than the
antibody alone (mAb) or the admixture
(mAb + cytotoxic agent unlinked)10
Scientists at Seattle Genetics are focused on parameters critical to the effective performance of ADCs,
including target antigen selection,3,4 linker stability5-7
Antibody-drug conjugates (ADCs) use a conditionally stable linker to combine the targeting specificity of
monoclonal antibodies with the tumor-killing power of potent cytotoxic agents.1,2
drugs to be delivered directly to tumor cells with minimal systemic toxicity.
This could allow potent
nation with methotrexate. Dr. Anas
Younes will present preliminary results
of the combination of brentuximab
vedotin, an anti-CD30 immunoconjugate,
with ABVD or AVD in
the treatment of patients with newly
diagnosed advanced-stage Hodgkin
lymphoma. Data on maximum tolerated
dose and safety profile will be
presented. But there is much more.
Can we use antibiotics and doublearmed
T-lymphocytes to treat aggressive
lymphomas? Helicobacter
pylori (Hp) is detected in about a
third of patients with primary gastric
diffuse large B-cell lymphoma,
and the incidence is even higher in
patients with concomitant mucosaassociated
lymphoid tissue (MALT)
lymphoma. While the role of Hperadicating
therapy is well established
in MALT lymphoma, the efficacy
of this approach is not known in
patients with DLBCL. Dr. Silvia Govi
will present the results of a multicenter
phase II trial suggesting that
antibiotic therapy can be used as the
sole treatment modality even in patients
with an aggressive histology.
One more etiologic agent associated
with a number of lymphoproliferative
disorders, is Epstein Barr virus
(EBV). Dr. Catherine Bollard will
show how immunotherapy with cytotoxic
T-lymphocytes targeting EBV
antigens is not only feasible but can
induce responses in patients with
EBV-positive lymphomas.
Tweets
from
#ASH11
Chewing on great career development
advice at #ASH11
Simultaneously exciting and
ulcer-inducing... – prknlot
At Successes in Bone Marrow
Failures Symposium. Good session
at #ASH11 – marrow
Excited to hear updates from
my colleagues attending @
ASH_hematology annual meeting.
#ASH11 – hayeslat
Loving 68 degree weather
and palm trees in San diego.
#ASH11 – alantanmd
Science editor en route to
#ASH11. If the crew needs to
ask “is there a doctor on the
plane?” they will be all SET. –
BioWorld
Kind of geeking out that
#ASH11 has its own iPhone
app! – deepfriedlard
Dr. Pro receives research funding
from Seattle Genetics and is a coauthor
of one of the papers mentioned above.
The future of drug treatment in cancer
Seattle Genetics is dedicated to improving the lives of people with cancer by developing
innovative therapies for hematologic malignancies and solid tumors.
Go to seattlegenetics.com for your complimentary, comprehensive, 15-slide
educational presentation. Just click on the download icon to get the slides
delivered to your personal computer or mobile device.
Go to seattlegenetics.com for your complimentary, comprehensive, 15-slide
educational presentation. Just click on the download icon to get the slides
delivered to your personal computer or mobile device.
Seattle Genetics is dedicated to improving the lives of people with cancer by developing
innovative therapies for hematologic malignancies and solid tumors.
Download ADC
scientific slide
deck >
Download ADC
scientific slide
deck >
TRIM
«« From Page A-14
Just landed for #ASH11 and
there is a guy in just boxers at the
baggage claim... – derekwimmer
just teach, but really ‘trade education’
with our international African colleagues
about hematologic diseases,”
Dr. Lund said about his experiences.
Next, Dr. Heather Ann Hume,
Here in #ASH11 waiting T-cell
lymphoma session. San Diego
CA – humbertosinco
Leadership in antibody-drug
conjugate development
www.seattlegenetics.comwww.seattlegenetics.com
REFERENCES: 1. Ducry L, Stump B. Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies.
Bioconjug Chem. 2010;21(1):5-13. 2. Wu AM, Senter PD. Arming antibodies: prospects and challenges for
immunoconjugates. Nat Biotechnol. 2005;23(9):1137-1146. 3. Carter P, Smith L, Ryan M. Identification and validation
of cell surface antigens for antibody targeting in oncology. Endocr Relat Cancer. 2004;11(4):659-687. 4. Carter PJ,
Senter PD. Antibody-drug conjugates for cancer therapy. Cancer J. 2008;14(3):154-169. 5. Alley SC, Benjamin DR,
Jeffrey SC, et al. Contribution of linker stability to the activities of anticancer immunoconjugates. Bioconjug Chem.
2008;19(3):759-765. 6. Chari RVJ. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem
Res. 2008;41(1):98-107. 7. Alley SC, Okeley NM, Senter PD. Antibody-drug conjugates: targeted drug delivery
for cancer. Curr Opin Chem Biol. 2010;14(4):529-537. 8. Senter PD. Potent antibody drug conjugates for cancer
therapy. Curr Opin Chem Biol. 2009;13(3):235-244. 9. Polson AG, Calemine-Fenaux J, Chan P, et al. Antibody-drug
conjugates for the treatment of non–Hodgkin’s lymphoma: target and linker-drug selection. Cancer Res. 2009;69(6):
2358-2364. 10. Doronina SO, Toki BE, Torgov MY, et al. Development of potent monoclonal antibody auristatin
conjugates for cancer therapy. Nat Biotechnol. 2003;21(7):778-784.
© 2011 Seattle Genetics, Inc., Bothell, WA 98021
All rights reserved.
Seattle Genetics andSeattle Genetics and
Printed in USA
© 2011 Seattle Genetics, Inc., Bothell, WA 98021
All rights reserved.
are US registered trademarks of Seattle Genetics, Inc.
US/ADC/2011/0030
US/ADC/2011/0030
are US registered trademarks of Seattle Genetics, Inc.
Printed in USA
REFERENCES: 1. Ducry L, Stump B. Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies.
Bioconjug Chem. 2010;21(1):5-13. 2. Wu AM, Senter PD. Arming antibodies: prospects and challenges for
immunoconjugates. Nat Biotechnol. 2005;23(9):1137-1146. 3. Carter P, Smith L, Ryan M. Identification and validation
of cell surface antigens for antibody targeting in oncology. Endocr Relat Cancer. 2004;11(4):659-687. 4. Carter PJ,
Senter PD. Antibody-drug conjugates for cancer therapy. Cancer J. 2008;14(3):154-169. 5. Alley SC, Benjamin DR,
Jeffrey SC, et al. Contribution of linker stability to the activities of anticancer immunoconjugates. Bioconjug Chem.
2008;19(3):759-765. 6. Chari RVJ. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem
Res. 2008;41(1):98-107. 7. Alley SC, Okeley NM, Senter PD. Antibody-drug conjugates: targeted drug delivery
for cancer. Curr Opin Chem Biol. 2010;14(4):529-537. 8. Senter PD. Potent antibody drug conjugates for cancer
therapy. Curr Opin Chem Biol. 2009;13(3):235-244. 9. Polson AG, Calemine-Fenaux J, Chan P, et al. Antibody-drug
conjugates for the treatment of non–Hodgkin’s lymphoma: target and linker-drug selection. Cancer Res. 2009;69(6):
2358-2364. 10. Doronina SO, Toki BE, Torgov MY, et al. Development of potent monoclonal antibody auristatin
conjugates for cancer therapy. Nat Biotechnol. 2003;21(7):778-784.
CHU Sainte-Justine, University of
Montreal, Montreal, Canada, discussed
the unique challenges in hospital
transfusion practices encountered
in Uganda’s largest referral
hospital. Dr. Jean-Pierre Allain, University
of Cambridge, United Kingdom,
ended the session by reviewing
national blood services in Sub-Saharan
Africa, discussing the issues surrounding
chronic blood shortages
and the lack of a stable health service
infrastructure to ensure the safety of
the blood supply.
Just got back from #ASH11 registration.
Loved the monitor for
the Twitter Feed. Are you following
@ASH_hematology?
Lisa_Palacios
–
Headed out to San Diego for
#ASH11. – jghoggatt
Drs. Garcia and Ghanny indicated no
relevant conflicts of interest.
Join the annual meeting
conversation on Twitter. Use
#ASH11 in your tweets from the
meeting. Follow ASH on
Twitter (@ash_hematology)
for Society news, meeting
information, advocacy updates,
and much more.
10/25/11 2:37 PM10/25/11 2:37 PM
lenges to providing SCD care even
when there is strong evidence for
improved outcomes.
Dr. Lottenberg will also discuss
the need to be aware of unintended
consequences when developing
quality indicators for SCD. “There
needs to be validation of outcome
measures. We need to assure quality
indicators serve to enhance the
capabilities of providers, rather
»» QUALITY Page A-18
Saturday, December 10, 2011
ASH NEWS DAILYAIL
Page A–15
®
®
Table of Contents for the Digital Edition of ASH News Daily - Monday, December 12, 2011
ASH News Daily - Monday, December 12, 2011
https://www.nxtbookmedia.com